Lexeo Therapeutics, Inc. Rings the Nasdaq Stock Market Closing Bell
Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease are treated, visits the Nasdaq MarketSite in Times Square. In honor of the occasion, R. Nolan Townsend, Lexeo Chief Executive Officer, rings the Closing Bell.